Statin therapy and infection-related mortality.

A. Corona

DOI: https://doi.org/10.1097/01.CCM.0000266836.34183.2A

IF: 8.8

2007-06-01

Critical Care Medicine

Abstract:

What problem does this paper attempt to address?

Effects of Statins on the Development of Sepsis and Organ Dysfunction in Hospitalized Older Patients in China

Qifeng Gui,Yunmei Yang,Jiajia Zhang

DOI: https://doi.org/10.1016/j.bjid.2016.12.008

IF: 3.257

2017-01-01

The Brazilian Journal of Infectious Diseases

Abstract:This study aimed to evaluate the protective role of statins on the development of sepsis and infection-related organ dysfunction and mortality in a hospitalized older Chinese population with bacterial infections. In this retrospective cohort study, 257 older patients with bacterial infection were divided into two groups: a statin group, those who had received statin therapy for ≥1 month before admission and continued receiving statin during hospitalization; and a non-statin group, those who had never received statin or used statin for <1 month prior to admission. A multivariate logistic regression analysis was performed to identify risk and protective factors for severe sepsis. A significantly lower incidence of organ dysfunction was found in the statin group, as compared with the non-statin group (13.3% vs 31.1%, respectively; p=0.002), corresponding to adjusted rates ratio of 0.32 (95% confidence interval [CI], 0.13-0.75; p=0.009). No significant difference was found between statin and non-statin groups in 30-day sepsis-related mortality (4.4% vs 10.2%, respectively; p=0.109), incidence of intensive care unit admission (13.3% vs 16.8%, respectively; p=0.469), or length of hospital stay (20.5 vs 25.9 days, respectively; p=0.61). Statins significantly reduced the development of sepsis and infection-related organ dysfunction in hospitalized older Chinese patients but did not reduce 30-day mortality, ICU admission incidence, or length of hospital stay.
Effect of Statins on In-Hospital Mortality in Elderly Chinese Patients with Sepsis: a Retrospective Cohort Study

Gui Qifeng,Yang Yunmei,Zhang Jiajia

DOI: https://doi.org/10.3877/cma.j.issn.1674-6880.2016.01.006

2016-01-01

Abstract:Objective To investigate the prognostic value of statins on elderly Chinese patients with sepsis. Methods A total of 212 elderly Chinese patients with sepsis hospitalized in First Affiliated Hospital, Zhejiang University School of Medicine, from March 2009 to March 2012 were enrolled into the study. Time to discharge from the hospital was selected as the primary endpoint. All the patients were divided into the death group and survival group, and the variables were compared between the two groups. The multivariate logistic regression was applied to assess the independent risk factors for death among the patients during the hospitalization. Results The proportion of the patients treated by statins continuously in the death group was significantly higher than that in the survival group [13.9% (5/36) vs. 34.7%(61/176), χ2=6.014, P=0.014], and the statins were the independent predictor for death during hospitalization (OR: 0.17; 95%CI: 0.04-0.85; P=0.03). Conclusion Statins may reduce the in-hospital mortality in elderly Chinese patients with sepsis.
Statin Therapy, Inflammation, and Outcomes in Patients Hospitalized for Covid-19: A Prospective Multicenter Cohort Study

Anis Ismail,Husam R Shadid,Yiyuan Huang,Christina G Hutten,Alexi Vasbinder,Ian Pizzo,Tonimarie Claire Catalan,Kristen Machado Diaz,Pennelope Kunkle,Mousumi Banerjee,Melvyn Rubenfire,Eric J Brandt,Geoffery Williams,Rodica Pop-Busui,Salim S Hayek

DOI: https://doi.org/10.1016/j.amjmed.2024.08.011

2024-08-21

Abstract:Background: Statins are lipid-lowering agents with with anti-inflammatory effects. Data surrounding the benefits of statins in patients with coronavirus disease 2019 (Covid-19) are conflicting. We sought to better understand the impact of statins in the context of Covid-19-related inflammation. Methods: We leveraged the International Study of Inflammation in Covid-19, a prospective multicenter cohort of patients hospitalized for Covid-19 between February 2020 and October 2022. Participants underwent systematic assessment of biomarkers of inflammation. We used logistic regression modeling and inverse probability-of-treatment weighting (IPTW) to examine the association between prior statin use and the composite outcome of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. Results: A total of 4,464 patients were included in the study, of whom 1,364 (27.5%) were taking a statin prior to admission. There were 1,061 primary outcome events, including 540 deaths, 854 mechanical ventilation and 313 renal replacement therapy. Amongst biomarkers of inflammation, statin use was associated solely with lower levels of soluble urokinase plasminogen activator receptor (suPAR) after adjusting for known confounders. In multivariable logistic regression analysis, statin use was associated with lower odds of the composite outcome (adjusted odds ratio (aOR) 0.63, 95%CI[0.53-0.76]) compared to patients not on statins. Findings were consistent with IPTW (aOR 0.92, 95%CI [0.89- 0.95]). The proportion of the effect of statin on the primary outcome mediated by suPAR was estimated at 31.5%. Conclusion: Prior-statin use is associated with improved outcomes and lower inflammation as measured by suPAR levels in patients hospitalized for Covid-19.
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.

Maria-Corina Serban,Lisandro D. Colantonio,Angelika D. Manthripragada,Keri L. Monda,Vera A. Bittner,Maciej Banach,Ligong Chen,Lei Huang,Ricardo Dent,Shia T. Kent,Paul Muntner,Robert S. Rosenson

DOI: https://doi.org/10.1016/j.jacc.2016.12.036

IF: 24

2017-01-01

Journal of the American College of Cardiology

Abstract:BACKGROUND Many patients report adverse reactions to, and may not tolerate, statin therapy. These patients may be at increased risk for coronary heart disease (CHD) events and mortality.OBJECTIVES This study evaluated the risk for recurrent myocardial infarction (MI), CHD events, and all-cause mortality in Medicare beneficiaries with statin intolerance and in those with high adherence to statin therapy.METHODS We studied 105,329 Medicare beneficiaries who began a moderate-or high-intensity statin dosage after hospitalization for MI between 2007 and 2013. Statin intolerance was defined as down-titrating statins and initiating ezetimibe therapy, switching from statins to ezetimibe monotherapy, having International Classification of Diseases, 9th revision, diagnostic codes for rhabdomyolysis or an antihyperlipidemic adverse event, followed by statin down-titration or discontinuation, or switching between >= 3 types of statins within 1 year after initiation. High statin adherence over the year following hospital discharge was defined as proportion of days covered >= 80%. Recurrent MI, CHD events (recurrent MI or a coronary revascularization procedure), and mortality were identified from 1 year after hospital discharge through December 2014.RESULTS Overall, 1,741 patients (1.65%) had statin intolerance, and 55,567 patients (52.8%) had high statin adherence. Over a median of 1.9 to 2.3 years of follow-up, there were 4,450 recurrent MIs, 6,250 CHD events, and 14,311 deaths. Compared to beneficiaries with high statin adherence, statin intolerance was associated with a 36% higher rate of recurrent MI (41.1 vs. 30.1 per 1,000 person-years, respectively), a 43% higher rate of CHD events (62.5 vs. 43.8 per 1,000 person-years, respectively), and a 15% lower rate of all-cause mortality (79.9 vs. 94.2 per 1,000 person-years, respectively). The multivariate-adjusted hazard ratios (HR) comparing beneficiaries with statin intolerance versus those with high statin adherence were 1.50 (95% confidence interval [CI]: 1.30 to 1.73) for recurrent MI, 1.51 (95% CI: 1.34 to 1.70) for CHD events, and 0.96 (95% CI: 0.87 to 1.06) for all-cause mortality.CONCLUSIONS Statin intolerance was associated with an increased risk for recurrent MI and CHD events but not all-cause mortality. (J Am Coll Cardiol 2017; 69: 1386-95) (C) 2017 by the American College of Cardiology Foundation.
Spectrophotometric determination of fluothane vapour

W. Kalow

DOI: https://doi.org/10.1007/BF03021125

1957-10-01

Abstract:
A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with Staphylococcus aureus bloodstream infection

Jianwei Su,Yixuan Wang,Wanping Zhong,Mengzhi Wang,Yanhong Wang

DOI: https://doi.org/10.5114/aoms/187004

2024-03-30

Archives of Medical Science

Abstract:Introduction There is insufficient evidence in statin on the treatment of Staphylococcus aureus (SA) infection, we observe and analyze the clinical outcomes and antibiotic resistance of SA bloodstream infections in patients who received statins. Material and methods A retrospective study was carried out in SA bloodstream infection of hospitalized patients from January 2018 to August 2023. The 30-day attributable mortality, 30-day all-cause mortality and clinical data of patients who received statins and non-statins were compared. Results A total of 74 patients with SA bloodstream infection were included, 32 (43.2%) patients received treatment with statins and 42 (56.8%) with non-statins. The incidence of methicillin-resistant SA (MRSA) was significantly lower in the statins group (15.6% vs. 38.1%, p = 0.034), however, no significant differences were observed in the mortality rate (p = 0.410). Conclusions This study revealed the superiority of statins in reducing incidence of MRSA among SA bloodstream infection patients, but statins do not improve the 30-day mortality rate.

medicine, general & internal
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies

André J Scheen

DOI: https://doi.org/10.1016/j.diabet.2020.101220

Abstract:Aims: People with cardiovascular disease or risk factors are at increased risk when exposed to SARS-CoV-2. Most are treated with statins, but the impact of these drugs on clinical outcomes of COVID-19 remains unclear. This report is therefore based on meta-analyses of retrospective observational studies aimed at investigating the impact of previous statin therapy in patients hospitalized for COVID-19. Methods: In studies reporting on the clinical outcomes of COVID-19 in statin users vs non-users, two endpoints have been used-in-hospital death rates, and disease severity as assessed by admission to intensive care units (ICUs)-with a special focus on patients with diabetes. Results: Regarding mortality, 13 studies were included in the meta-analysis for a total of 10,829 statin users (2517 deaths) and 31,893 non-users (7516 deaths): univariate analysis showed no statistically significant reduction in deaths (OR: 0.97, 95% CI: 0.92-1.03), although between-study heterogeneity was high (I² = 97%). As for disease severity, 11 studies were selected for a total of 3462 statin users (724 endpoints) and 10,560 non-users (1763 endpoints): here again, univariate analysis showed no reduction in severity (OR: 1.09, 95% CI: 0.99-1.22; I² = 93%). Collectively, in 10 studies using multivariable analysis adjusted for the more prevalent baseline risk factors among statin users, lower OR values were reported than with univariate analyses (0.73 ± 0.31 vs 1.44 ± 0.84, respectively; P = 0.0028; adjusted OR: P = 0.0237 vs non-users). Limited but conflicting findings were observed for diabetes patients. Conclusion: Although no significant reductions in either in-hospital mortality or COVID-19 severity were reported among statin users compared with non-users after univariate comparisons, such reductions were observed after adjusting for confounding factors. These highly heterogeneous observational findings now require confirmation by ongoing randomized clinical trials.
The impact of statin use on sepsis mortality

Mohan Li,Raymond Noordam,Stella Trompet,Elizabeth M Winter,J Wouter Jukema,M Sesmu Arbous,Patrick C N Rensen,Sander Kooijman

DOI: https://doi.org/10.1016/j.jacl.2024.07.006

2024-07-27

Abstract:Background: Statins exert pleiotropic anti-inflammatory and antioxidant effects in addition to their cholesterol-lowering properties. This study aimed to investigate whether statin use is associated with improved outcomes of sepsis. Methods: Data from sepsis patients were extracted from the Medical Information Mart for Intensive Care IV database. Patients with a history of receiving prescriptions for statins (i.e. atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin) were matched with non-users using propensity-score matching, to balance confounding factors between the groups. Mendelian Randomization (MR) analyses were performed using information from the UK Biobank dataset to explore the potential causal link between low-density lipoprotein cholesterol (LDL-C) levels and LDL-C lowering effects via genetically inhibiting β‑hydroxy β-methylglutaryl-coenzyme A reductase and the susceptibility to sepsis, and the sepsis-related 28-day mortality. Main results: 90-day mortality rate was lower among the 10,323 statin users when compared to matched non-users [hazard ratio (HR): 0.612, 95 % CI: 0.571 to 0.655]. In-hospital mortality was also lower for statin users compared to non-users (11.3% vs. 17.8 %, p < 0.0001, HR: 0.590, 95 % CI: 0.548 to 0.634). Statin use was associated with better outcome in all investigated subpopulations apart from patients with severe liver disease. MR analyses further pointed toward pleiotropic effects beyond lipid-lowering effects of statins on sepsis-related outcomes. Conclusions: Statin use is associated with improved outcomes following sepsis-related ICU admission, most likely from its pleiotropic properties, characterized by lower 90-day and in-hospital mortality among statin users.
Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts

Ahmad Fariz Malvi Zamzam Zein,Catur Setiya Sulistiyana,Uswatun Khasanah,Arief Wibowo,Michael Anthonius Lim,Raymond Pranata

DOI: https://doi.org/10.1136/postgradmedj-2021-140409

Abstract:Purpose: Statin potentially improved outcome in patients with COVID-19. Patients who receive statin generally have a higher proportion of comorbidities than those who did not, which may introduce bias. In this meta-analysis, we aimed to investigate the association between statin use and mortality in patients with COVID-19 by pooling the adjusted effect estimates from propensity-score matching (PSM) matched studies or randomised controlled trials to reduce bias. Methods: A systematic literature search using the PubMed, Scopus and Embase databases were performed up until 1 March 2021. Studies that were designed the study to assess statin and mortality using PSM with the addition of Inverse Probability Treatment Weighting or multivariable regression analysis on top of PSM-matched cohorts were included. The effect estimate was reported in term of relative risk (RR). Results: 14 446 patients were included in the eight PSM-matched studies. Statin was associated with decreased mortality in patients with COVID-19 (RR 0.72 (0.55, 0.95), p=0.018; I2: 84.3%, p<0.001). Subgroup analysis in patients receiving statin in-hospital showed that it was associated with lower mortality (RR 0.71 (0.54, 0.94), p=0.030; I2: 64.1%, p<0.025). The association of statin and mortality was not significantly affected by age (coefficient: -0.04, p=0.382), male gender (RR 0.96 (0.95, 1.02), p=0.456), diabetes (RR 1.02 (0.99, 1.04), p=0.271) and hypertension (RR 1.01 (0.97, 1.04), p=0.732) in this pooled analysis. Conclusion: In this meta-analysis of PSM-matched cohorts with adjusted analysis, statin was shown to decrease the risk of mortality in patients with COVID-19. Prospero registration number: CRD42021240137.
Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases

Ching-Chung Hsiao,Jih-Kai Yeh,Yan-Rong Li,Wei-Chiao Sun,Pei-Yi Fan,Chieh-Li Yen,Jung-Sheng Chen,Chihung Lin,Kuan-Hsing Chen

DOI: https://doi.org/10.3389/fphar.2022.996237

IF: 5.6

2022-09-30

Frontiers in Pharmacology

Abstract:Background: Statins are commonly used for cardiovascular disease (CVD) prevention. Observational studies reported the effects on sepsis prevention and mortality improvement. Patients with chronic kidney disease (CKD) are at high risk for CVD and infectious diseases. Limited information is available for statin use in patients with non-dialysis CKD stage V. Method: The retrospective observational study included patients with non-dialysis CKD stage V, with either de novo statin use or none. Patients who were prior statin users and had prior cardiovascular events were excluded. The key outcomes were infection-related hospitalization, major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, hospitalization for heart failure, or non-fatal stroke), and all-cause mortality. The data were retrieved from the Chang Gung Research Database (CGRD) from January 2001 to December 2019. Analyses were conducted with Cox proportional hazard regression models in the propensity score matching (PSM) cohort. Result: A total of 20,352 patients with CKD stage V were included (1,431 patients were defined as de novo statin users). After PSM, 1,318 statin users were compared with 1,318 statin non-users. The infection-related hospitalization (IRH) rate was 79.3 versus 94.3 per 1,000 person-years in statin users and statin non-users, respectively [hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.74–0.93, p = 0.002]. The incidence of MACE was 38.9 versus 55.9 per 1,000 person-years in statin users and non-users, respectively (HR, 0.72; 95% CI 0.62–0.83, p < 0.001). The all-cause mortality did not differ between statin users and non-users, but statin users had lower infection-related mortality than non-users (HR, 0.59; 95% CI 0.38–0.92, p = 0.019). Conclusion: De novo use of statin in patients with non-dialysis CKD stage V reduced the incidence of cardiovascular events, hospitalization, and mortality for infectious disease. The study results reinforced the benefits of statin in a wide range of patients with renal impairment before maintenance dialysis.

pharmacology & pharmacy
Statin use and clinical outcomes in hospitalized COVID-19 patients

Khalid S. Alshaalan,Rahaf F. Alkahtani,Renad F. Althobaiti,Rana A. Aldhahi,Fatimah Z. Rebh,Sarah S. Algezlan,Salma M. Alanazi,Shawg S. Alrumaih,Basma A. Alturki,Abdullah S. Alahmadi,Raneem A. Alanazi,Alaa H. Al Ali,Othman M. Alshabanah

DOI: https://doi.org/10.15537/smj.2024.45.2.20230589

2024-02-01

Saudi Medical Journal

Abstract:OBJECTIVES: To investigate the relationship between statin use and coronavirus disease-19 (COVID-19) severity.METHODS: This was a retrospective study of adult patients with confirmed COVID-19 who were hospitalized at Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia. The study was carried out from July - September 2020. Antecedent statin use was evaluated using medication information available in the electronic medical records.RESULTS: In this retrospective study, we collected data from 689 patients hospitalized with COVID-19. Among the patients, 56.2% of them were non-Saudi and 67.3% were males. The mean age of the patients was 53.7 years. The most common comorbidities among patients with COVID-19 at admission were hypertension (65.2%) and diabetes mellitus (65%). Among these patients, 155 (22.5%) patients received statins during hospitalization and 79.7% of them received corticosteroids. Receiving statins significantly increased the risk of intensive care unit's admission by 1.64 times, intubation by 1.76 times, developing complications by 2.48 times, and mortality by 3.16 times.CONCLUSION: Statins are associated with a higher risk of mortality and morbidity among patients hospitalized for COVID-19.

medicine, general & internal
Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease

Lan Shen,Lin Qiu,Li Wang,Hengye Huang,Dong Liu,Ying Xiao,Yi Liu,Jingjin Jin,Xiulan Liu,Dao Wen Wang,Ben He,Ning Zhou

DOI: https://doi.org/10.1038/s41598-021-02534-2

IF: 4.6

2021-12-01

Scientific Reports

Abstract:Abstract The worsening progress of coronavirus disease 2019 (COVID-19) is attributed to the proinflammatory state, leading to increased mortality. Statin works with its anti-inflammatory effects and may attenuate the worsening of COVID-19. COVID-19 patients were retrospectively enrolled from two academic hospitals in Wuhan, China, from 01/26/2020 to 03/26/2020. Adjusted in-hospital mortality was compared between the statin and the non-statin group by CHD status using multivariable Cox regression model after propensity score matching. Our study included 3133 COVID-19 patients (median age: 62y, female: 49.8%), and 404 (12.9%) received statin. Compared with the non-statin group, the statin group was older, more likely to have comorbidities but with a lower level of inflammatory markers. The Statin group also had a lower adjusted mortality risk (6.44% vs. 10.88%; adjusted hazard ratio [HR] 0.47; 95% CI, 0.29–0.77). Subgroup analysis of CHD patients showed a similar result. Propensity score matching showed an overall 87% (HR, 0.13; 95% CI, 0.05–0.36) lower risk of in-hospital mortality for statin users than nonusers. Such survival benefit of statin was obvious both among CHD and non-CHD patients (HR = 0.30 [0.09–0.98]; HR = 0.23 [0.1–0.49], respectively). Statin use was associated with reduced in-hospital mortality in COVID-19. The benefit of statin was both prominent among CHD and non-CHD patients. These findings may further reemphasize the continuation of statins in patients with CHD during the COVID-19 era.

multidisciplinary sciences
Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction

Samanta Ortega-Hernández,Sonia González-Sosa,Alicia Conde-Martel,Joan Carles Trullàs,Pau Llàcer,José Pérez-Silvestre,José Carlos Arévalo-Lorido,Jesús Casado,Francesc Formiga,Luis Manzano,Noel Lorenzo-Villalba,Manuel Montero-Pérez-Barquero

DOI: https://doi.org/10.3390/jcm13195844

IF: 3.9

2024-10-01

Journal of Clinical Medicine

Abstract:Background: Heart failure (HF) with preserved ejection fraction (pEF) has lacked effective treatments for reducing mortality. However, previous studies have found an association between statin use and decreased mortality in patients with HFpEF. The aim of this study was to analyse whether statin therapy is associated with a reduction in mortality in these patients and whether the effect differs according to the presence or absence of ischaemic heart disease (IHD). Methods: We analysed data from the National Registry of Heart Failure, a prospective study that included patients admitted for HF in Internal Medicine units nationwide. Patients with HFpEF were classified according to the use of statins, and the differences between the two groups were analysed. A multivariable analysis was performed using Cox regression to assess factors independently related to mortality. Results: A total of 2788 patients with HFpEF were included; 63% of them were women with a mean age of 80.1 (±7.8) years. The statin-treated group (40.2%) was younger, with better functional status, and had a more common diagnosis of vascular disease and lower frequency of atrial fibrillation. The most frequent aetiology of HF in both groups was the hypertensive one. Nevertheless, ischaemic HF was more common in those who received statins (24.8% vs. 9.6%; p < 0.001). Multivariable analysis showed lower mortality at the 1-year follow-up in statin-treated patients (OR: 0.74; 95%CI: 0.61–0.89; p = 0.002). This association was observed in patients without IHD (p < 0.001) but not in those with IHD (p = 0.11). Conclusions: Statins are associated with a decrease in total mortality in patients with HFpEF. This benefit occurs mainly in those without IHD.

medicine, general & internal
Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study

Yongzhen Fan,Tao Guo,Feifei Yan,Ming Gong,Xin A. Zhang,Chenze Li,Tao He,Huimin Luo,Lin Zhang,Ming Chen,Xiaoyan Wu,Hairong Wang,Ke-Qiong Deng,Jiao Bai,Lin Cai,Zhibing Lu

DOI: https://doi.org/10.3389/fmed.2020.584870

IF: 3.9

2020-11-17

Frontiers in Medicine

Abstract:Background: Statins have multiple protective effects on inflammation, immunity and coagulation, and may help alleviate pneumonia. However, there was no report focusing on the association of statin use with in-hospital outcomes of patients with coronavirus disease 2019 (COVID-19). We investigated the association between the use of statins and in-hospital outcomes of patients with COVID-19. Methods: In this retrospective case series, consecutive COVID-19 patients admitted at 2 hospitals in Wuhan, China, from March 12, 2020 to April 14, 2020 were analyzed. A 1:1 matched cohort was created by propensity score-matched analysis. Demographic data, laboratory findings, comorbidities, treatments and in-hospital outcomes were collected and compared between COVID-19 patients taking and not taking statins. Result: A total of 2,147 patients with COVID-19 were enrolled in this study. Of which, 250 patients were on statin therapy. The mortality was 2.4% (6/250) for patients taking statins while 3.7% (70/1,897) for those not taking statins. In the multivariate Cox model, after adjusting for age, gender, admitted hospital, comorbidities, in-hospital medications and blood lipids, the risk was lower for mortality (adjusted HR, 0.428; 95% CI, 0.169-0.907; P = 0.029), acute respiratory distress syndrome (ARDS) (adjusted HR, 0.371; 95% CI, 0.180-0.772; P = 0.008) or intensive care unit (ICU) care (adjusted HR, 0.319; 95% CI, 0.270-0.945; P = 0.032) in the statin group vs. the non-statin group. After propensity score-matched analysis based on 18 potential confounders, a 1:1 matched cohort (206:206) was created. In the matched cohort, the Kaplan-Meier survival curves showed that the use of statins was associated with better survival (P = 0.025). In a Cox regression model, the use of statins was associated with lower risk of mortality (unadjusted HR, 0.254; 95% CI, 0.070-0.926; P = 0.038), development of ARDS (unadjusted HR, 0.240; 95% CI, 0.087-0.657; P = 0.006), and admission of ICU (unadjusted HR, 0.349; 95% CI, 0.150-0.813; P = 0.015). The results remained consistent when being adjusted for age, gender, total cholesterol, triglyceride, low density lipoprotein cholesterol, procalcitonin, and brain natriuretic peptide. The favorable outcomes in statin users remained statistically significant in the first sensitivity analysis with comorbid diabetes being excluded in matching and in the second sensitivity analysis with chronic obstructive pulmonary disease being added in matching. Conclusion: In this retrospective analysis, the use of statins in COVID-19 patients was associated with better clinical outcomes and is recommended to be continued in patients with COVID-19.

medicine, general & internal
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry

Carmine Siniscalchi,Behnood Bikdeli,David Jiménez,José María Suriñach,Pablo Demelo-Rodríguez,Farès Moustafa,Aída Gil-Díaz,Alberto García-Ortega,Hanh My Bui,Manuel Monreal,RIETE Investigators

DOI: https://doi.org/10.1016/j.thromres.2024.02.024

IF: 10.407

2024-02-25

Thrombosis Research

Abstract:Background The association between statin use and mortality in patients with deep vein thrombosis (DVT) has not been rigorously evaluated. Methods We used the data in the RIETE registry to examine the association between statin use and mortality at 3 months. We used mixed effects survival models accounting for clinical covariates and clustering of patients in enrolling centers. Results From January 2009 through April 2022, there were 46,440 patients with isolated DVT in RIETE (in the lower-limbs 42,291, in the upper limbs 4149). Of these, 21 % and 18 %, respectively, were using statins. Statin users were older than non-users (72 ± 12 vs. 62 ± 18 years), and more likely had diabetes, hypertension, prior myocardial infarction or ischemic stroke, or were receiving antiplatelets. The 3-month mortality rates were: 6.0 % vs. 5.8 %, respectively. On multilevel multivariable analysis, the adjusted hazard ratio (aHR) for all-cause death in statin users vs. non-users was 0.77 (95%CI: 0.69–0.86). The 3-month risk of death in statin users was significantly lower than in non-users in patients with upper-limb DVT (aHR: 0.81; 95%CI: 0.72–0.91), distal lower-limb DVT (aHR: 0.48; 95%CI: 0.32–0.72), or proximal lower-limb DVT (aHR: 0.69; 95%CI: 0.50–0.95), and in those receiving simvastatin (aHR: 0.73; 95%CI: 0.60–0.90), atorvastatin (aHR: 0.70; 95%CI: 0.59–0.85), or rosuvastatin (aHR: 0.47; 95%CI: 0.27–0.80). Major bleeding, used as a falsification endpoint, did not show an association with use of statins at 3-month follow-up. Conclusions Statin users with isolated DVT were at significantly lower risk for death at 3 months than non-users.

peripheral vascular disease,hematology
Association between the use of statins and in-hospital mortality risk in patients with sepsis-induced coagulopathy during ICU stays: a study based on medical information mart for intensive care database

Yan Yao,Xi Zhao,Mengjue Wang,Fanfan Zhou,Chengfeng Li,Xudong Le,Siquan Zhang

DOI: https://doi.org/10.1186/s12879-024-09636-y

2024-07-25

Abstract:Background: The objective of this study was to explore the correlation between statin administration in the intensive care unit (ICU) setting and the in-hospital mortality risk of patients suffering from sepsis-induced coagulopathy (SIC). Methods: Utilizing a retrospective cohort study design, this investigation collected data from the Medical Information Mart for Intensive Care (MIMIC)-IV spanning 2008 to 2019. The diagnosis of SIC was established based on a SIC score of 4 or above. Statin usage during the ICU period was extracted from the prescription records based on the keywords of statin medications. The primary endpoint analyzed was the in-hospital mortality within the ICU, characterized by any death occurring during the ICU admission. Results: During the follow-up, which had a median duration of approximately 7.28 days, 18.19% of the 4,777 SIC patients died in the ICU. Statin was linked with a decrease in the risk of in-hospital mortality for SIC patients in the ICU [hazard ratio (HR): 0.73, 95% confidence interval (CI): 0.60-0.89, P = 0.002]. Relative to rosuvastatin, the use of atorvastatin (HR: 0.54, 95% CI: 0.34-0.85, P = 0.008) or simvastatin (HR: 0.55, 95% CI: 0.33-0.92, P = 0.024), as well as combinations of multiple statins (HR: 0.36, 95% CI: 0.15-0.86, P = 0.022), was associated with a reduction in ICU in-hospital mortality risk. Subgroup analysis also suggested that the use of atorvastatin, simvastatin, or a combination of statins had an advantage over rosuvastatin in reducing ICU in-hospital mortality in SIC patients older than 65 years of age or SIC patients with respiratory failure or cardiogenic shock (all P < 0.05). Conclusion: The present study supports the potential benefits of statin use in mortality in SIC patients during ICU stays. The study encourages clinicians to consider the benefits of statins and supports the ongoing exploration of statins for enhanced outcomes in critical care settings.
Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients

Ut-Sam Lao,Chak-Fun Law,Daniel T Baptista-Hon,Brian Tomlinson

DOI: https://doi.org/10.3390/jcm11185454

2022-09-16

Abstract:There is mounting evidence that statin use is beneficial for COVID-19 outcomes. We performed a systematic review and meta-analysis to evaluate the association between statin use and mortality, intensive care unit (ICU) admission and mechanical ventilation in COVID-19 patients, on studies which provided covariate adjusted effect estimates, or performed propensity score matching. We searched PubMed, Embase, Web of Science and Scopus for studies and extracted odds or hazard ratios for specified outcome measures. Data synthesis was performed using a random-effects inverse variance method. Risk of bias, heterogeneity and publication bias were analyzed using standard methods. Our results show that statin use was associated with significant reductions in mortality (OR = 0.72, 95% CI: 0.67-0.77; HR = 0.74, 95% CI: 0.69, 0.79), ICU admission (OR = 0.94, 95% CI: 0.89-0.99; HR = 0.76, 95% CI: 0.60-0.96) and mechanical ventilation (OR = 0.84, 95% CI: 0.78-0.92; HR = 0.67, 95% CI: 0.47-0.97). Nevertheless, current retrospective studies are based on the antecedent use of statins prior to infection and/or continued use of statin after hospital admission. The results may not apply to the de novo commencement of statin treatment after developing COVID-19 infection. Prospective studies are lacking and necessary.
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Xiao-Jing Zhang,Juan-Juan Qin,Xu Cheng,Lijun Shen,Yan-Ci Zhao,Yufeng Yuan,Fang Lei,Ming-Ming Chen,Huilin Yang,Liangjie Bai,Xiaohui Song,Lijin Lin,Meng Xia,Feng Zhou,Jianghua Zhou,Zhi-Gang She,Lihua Zhu,Xinliang Ma,Qingbo Xu,Ping Ye,Guohua Chen,Liming Liu,Weiming Mao,Youqin Yan,Bing Xiao,Zhigang Lu,Gang Peng,Mingyu Liu,Jun Yang,Luyu Yang,Changjiang Zhang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Xiang Wei,Bing-Hong Zhang,Xin Zhang,Juan Yang,Guang-Nian Zhao,Peng Zhang,Peter P. Liu,Rohit Loomba,Yan-Xiao Ji,Jiahong Xia,Yibin Wang,Jingjing Cai,Jiao Guo,Hongliang Li

DOI: https://doi.org/10.1016/j.cmet.2020.06.015

IF: 29

2020-08-01

Cell Metabolism

Abstract:Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after propensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and randomized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic.

cell biology,endocrinology & metabolism
Impact of Early Statin Therapy on Inhospital and Follow-Up Outcomes for Acute Coronary Syndrome Patients Undergoing Revascularization

吴嘉慧,聂绍平,康俊萍,吕强,杜昕,贾长琪,刘小慧,吴学思,董建增,马长生

DOI: https://doi.org/10.3969/j.issn.1674-3474.2008.07.002

2008-01-01

Abstract:Objective To evaluate the effects of statin treatment initiated in hospital on acute coronary syndrome patients who received revascularization Methods Non-ST segment elevation on acute coronary syndrome patients who received revascularization in our hospital and whose low density lipoprotein cholesterol was lower than 100 mg/dL were included.These patients were divided into two groups,the statin group received statin therapy in hospital(n=668) and the no-statin group did not receive statin treatment(n=453).The major adverse cardiovascular and cerebral vascular events were defined as mortality,acute myocardial infarction,revasualization and stroke.Results The occurrence of in-hospital major adverse cardiovascular and cerebral vascular events and the mortality in the follow-up period were significantly reduced in the statin group(P0.05,P0.01).Cumulative mortality(in-hospital and follow-up period) also decreased in the statin-group(P0.01).In logistic regression analysis,statin treatment initiated in hospital was associated with the reduction in cumulative mortality and mortality of the follow-up period(HR,0.471;95CI,0.245～0.906;P0.05 vs HR,0.328;95CI,0.143～0.753;P0.01).Conclusion Early statin treatment in patients with non-ST segment elevation on acute coronary syndrome undergoing revascularization is associated with the reduction in hospital major adverse cardiovascular and cerebral vascular events and cumulative mortality and mortality of the follow-up period.
Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data

Adovich Rivera,Omar Al-Heeti,Matthew J Feinstein,Janna Williams,Babafemi Taiwo,Chad Achenbach,Lucia Petito

DOI: https://doi.org/10.1136/bmjopen-2024-085547

IF: 3.006

2024-10-02

BMJ Open

Abstract:Objective We assessed the association of early statin initiation with inpatient mortality among hospitalised COVID-19 patients. Design, setting and participants This observational study emulated a hypothetical target trial using electronic health records data from Northwestern Medicine Health System, Illinois, 2020–2022. We included patients who were ≥40 years, admitted ≥48 hours for COVID-19 from March 2020 to August 2022 and had no evidence of statin use before admission. Interventions Individuals who initiated any statins within 48 hours of admission were compared with individuals who did not initiate statins during this period. Primary outcome measures Inpatient mortality at hospital days 7, 14, 21 and 28 were determined using hospital records. Risk differences between exposure groups were calculated using augmented inverse propensity weighting (AIPW) with SuperLearner. Results A total of 8893 individuals (24.5% early statin initiators) were included. Early initiators tended to be older, male and have higher comorbidity burdens. Unadjusted day 28 mortality was higher in early initiators (6.0% vs 3.6%). Adjusted analysis showed slightly higher inpatient mortality risk at days 7 (RD: 0.5%, 95% CI: 0.2 to 0.8) and 21 (RD: 0.6%, 95% CI: 0.04 to 1.1), but not days 14 (RD: 0.4%, 95% CI: –0.03 to 0.9) and 28 (RD: 0.4%, 95% CI: –0.2 to 1.1). Sensitivity analyses using alternative modelling approaches showed no difference between groups. Conclusions Early statin initiation was not associated with lower mortality contrasting with findings of previous observational studies. Trial emulation helped in identifying and addressing sources of bias incompletely addressed by previous work. Statin use may be indicated for other conditions but not COVID-19.

medicine, general & internal

Statin therapy and infection-related mortality.

Effects of Statins on the Development of Sepsis and Organ Dysfunction in Hospitalized Older Patients in China

Effect of Statins on In-Hospital Mortality in Elderly Chinese Patients with Sepsis: a Retrospective Cohort Study

Statin Therapy, Inflammation, and Outcomes in Patients Hospitalized for Covid-19: A Prospective Multicenter Cohort Study

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.

Spectrophotometric determination of fluothane vapour

A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with Staphylococcus aureus bloodstream infection

Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies

The impact of statin use on sepsis mortality

Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts

Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases

Statin use and clinical outcomes in hospitalized COVID-19 patients

Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease

Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction

Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study

Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry

Association between the use of statins and in-hospital mortality risk in patients with sepsis-induced coagulopathy during ICU stays: a study based on medical information mart for intensive care database

Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Impact of Early Statin Therapy on Inhospital and Follow-Up Outcomes for Acute Coronary Syndrome Patients Undergoing Revascularization

Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data